5-chloro-2-hydroxynicotinic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 162286 |
| CHEMBL ID | 5183219 |
| SCHEMBL ID | 329752 |
| SCHEMBL ID | 21416921 |
| MeSH ID | M0169526 |
| Synonym |
|---|
| AC-3577 |
| 5-chloro-2-hydroxynicotinic acid |
| MAYBRIDGE1_008644 , |
| SR-01000641843-1 |
| 38076-80-1 |
| 5-chloro-2-hydroxy-3-pyridinecarboxylic acid |
| C2339 |
| HMS566A20 |
| AKOS005070951 |
| 5-chloro-2-oxo-1h-pyridine-3-carboxylic acid |
| A6462 |
| 5-chloro-2-hydroxy-nicotinic acid;5-chloro-2-hydroxynicotinic acid |
| AKOS005257269 |
| 5-chloro-2-hydroxypyridine-3-carboxylic acid |
| 5-chloro-2-oxo-1,2-dihydro-3-pyridinecarboxylic acid |
| 5-chloro-2-hydroxynicotinicacid |
| 3-pyridinecarboxylic acid, 5-chloro-1,2-dihydro-2-oxo- |
| CCG-52623 |
| 5-chloro-2-oxo-1,2-dihydropyridine-3-carboxylic acid |
| AM20051128 |
| AB04751 |
| CL0214 |
| FT-0620254 |
| SCHEMBL329752 |
| AS-5148 |
| SY007420 |
| mfcd00204158 |
| 5- chloro-2-hydroxynicotinic acid |
| 5-chloro-2-hydroxy-nicotinic acid |
| XBHXNMLFJZTSAS-UHFFFAOYSA-N |
| 7E-336S |
| F8884-2030 |
| J-517309 |
| 5-chloro-2-hydroxynicotinic acid, aldrichcpr |
| DTXSID60191483 |
| CS-W002510 |
| CHEMBL5183219 , |
| SCHEMBL21416921 |
| 5-chloro-2-hydroxy nicotinic acid |
| bdbm50591484 |
| EN300-221587 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | Kd | 680.0000 | 0.0001 | 2.1016 | 40.2910 | AID1858237 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoskeleton | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| nucleus | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| nucleus | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| nucleoplasm | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| cytoplasm | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| nuclear speck | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| axon | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| dendrite | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| ribonucleoprotein complex | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1858237 | Binding affinity to human DYRK1A (127 to 485 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as dissociation constant by isothermal titration calorimetry assay | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21 | Screening of a Halogen-Enriched Fragment Library Leads to Unconventional Binding Modes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||